Back to Trials
NCT05517928NARecruitingAccepts Healthy Volunteers

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

Mayo Clinic

Start Date

3/3/2023

Completion Date

12/1/2026

Summary

The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Individuals on an unrestricted regular diet with no dietary restrictions (vegan, low FODMAP, gluten free, dairy-free etc) or other fad diets (e.g., keto, intermittent fasting, etc.). * Healthy subjects will be screened for current or chronic GI symptoms using a 16-item questionnaire. * Only those with an absence of symptoms will eligible to participate. Exclusion Criteria: * For healthy volunteers, will include prior surgery altering the esophagus, stomach, and intestine (except appendectomy). * Chronic daily use of medications affecting GI secretion or motor function. * The presence of any GI-motility affecting systemic diseases or untreated psychiatric disease. * Pregnancy.

Interventions

DRUG

Omeprazole

DIETARY_SUPPLEMENT

Lactobacillus rhamnosus GG

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy

Locations

Mayo Clinic Arizona

Scottsdale, Arizona 85259

United States